RTI-371 是一种可穿过血脑屏障的高选择性非典型多巴胺转运蛋白 (dopamine transporter; DAT) 抑制剂,对转染人类 DAT 的细胞系表现出强效抑制作用 (IC50 = 8.7 nM),对大鼠 DAT 的结合亲和力 Ki 值为 7.81 nM,同时也是人类大麻素 1 号受体 (human cannabinoid 1 receptor; hCB1 receptor) 的正向变构调节剂,能够以浓度依赖性方式增强大麻素受体激动剂的活性,可用于帕金森病 (Parkinson's disease) 的相关研究。
产品编号: MS-L66529 CAS No.: 652978-45-5 分子式: C24H25ClN2O 分子量: 392.92
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

RTI-371 是一种可穿过血脑屏障的高选择性非典型多巴胺转运蛋白 (dopamine transporter; DAT) 抑制剂,对转染人类 DAT 的细胞系表现出强效抑制作用 (IC50 = 8.7 nM),对大鼠 DAT 的结合亲和力 Ki 值为 7.81 nM,同时也是人类大麻素 1 号受体 (human cannabinoid 1 receptor; hCB1 receptor) 的正向变构调节剂,能够以浓度依赖性方式增强大麻素受体激动剂的活性,可用于帕金森病 (Parkinson's disease) 的相关研究。

生物实验数据

生物活性 RTI-371 is a highly selective atypical dopamine transporter (DAT) inhibitor that crosses the blood-brain barrier, exhibits potent inhibitory activity against cell lines transfected with human DAT (IC50 = 8.7 nM), and has a binding affinity Ki value of 7.81 nM for rat DAT; it is also a positive allosteric modulator of the human cannabinoid 1 receptor (hCB1 receptor) that enhances cannabinoid receptor agonist activity in a concentration-dependent manner, and can be used for research related to Parkinson's disease.
IC50 & Target

DAT

7.81 nM (Ki)

DAT

8.7 nM (IC50)

NET

880 nM (Ki)

NET

3990 nM (IC50)

SERT

50200 nM (Ki)

SERT

> 100,000 nM (IC50)

σ1

15800 nM (Ki)

σ2

353 nM (Ki)

Muscarinic 1 Receptor

11000 nM (Ki)

hCB1-R

 

体外研究
(In Vitro)

RTI-371 (1-10 μM;预孵育 15 min) 在稳定表达 hCB1 的 RD-HGA16 细胞中无内在活性,但作为 CB1 的正向变构调节剂,可使大麻素受体激动剂 CP55940 的效能提升 36%,同时增强合成大麻素受体激动剂 WIN55212-2 介导的 hCB1 受体激活。
RTI-371 (10 μM;预孵育 15 min) 在稳定表达 hMOR 的 RD-HGA16 细胞中对 μ-阿片受体选择性激动剂 DAMGO (MS-P78705) 诱导的 hMOR 信号无显著影响,进一步证实其对 CB1 的选择性。
RTI-371 (1.0和10 μM;预孵育 20 min 后共处理 30 min) 在 HEK293 细胞中增强 maleimide-PEO2-biotin 对 DAT 的标记,并在突变细胞中进一步增加 DAT 标记,提示其可稳定 DAT 外向构象。

体内研究
(In Vivo)

RTI-371 (30 mg/kg;腹腔注射;单次给药) 在大鼠中可穿过血脑屏障,并在尾状核中置换体内 [125I]RTI-55 的结合,证实其可进入中枢神经系统并作用于 DAT 相关位点。
RTI-371 (1.0-170 mg/kg;腹腔注射;单次给药) 在 CD-1 小鼠及 Swiss-Webster 小鼠中仅产生轻微至弱的运动刺激效应,并表现为延迟性、低幅度的水平运动增加。
RTI-371 (3.0-100 mg/kg;腹腔注射;单次给药) 在 Swiss-Webster 小鼠中部分替代神经活性物质的辨别刺激作用,最大可达约 60-68% 的药物杠杆反应,并呈剂量依赖性降低反应速率。
RTI-371 (0.01-1.0 mg/kg/注射;静脉注射;自我给药程序) 在雄性 Sprague-Dawley 大鼠中不维持自我给药行为,其反应水平接近生理盐水,提示缺乏强化作用。
RTI-371 (1.0-17 mg/kg;腹腔注射;单次给药) 在雄性 Sprague-Dawley 大鼠中剂量依赖性抑制神经活性物质自我给药,并产生不可克服的拮抗作用,使剂量反应曲线整体下移。
RTI-371 (3.0-56 mg/kg;腹腔注射;[125I]RTI-121 静脉注射示踪;单次给药) 在 Swiss-Webster 小鼠中产生剂量与时间依赖性的 DAT 占据效应,在纹状体达到最大结合位点占据,并表现出较慢脑进入速率。
RTI-371 (3.0-30 mg/kg;腹腔注射;单次给药) 在野生型及 CB1 受体敲除小鼠中均可增加运动活动,且无基因型差异。

Animal Model: Locomotor activity screening model (male CD-1 mice)
Dosage: Up to 30 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Displayed little or no effect on mouse horizontal locomotor activity, showing a poor correlation between locomotor stimulation and DAT inhibition.
Normalized locomotor stimulation score was reported as 5% (± 2%) of the maximum stimulation observed with 30 mg/kg cocaine.
Animal Model: In vivo [125I]RTI-55 displacement binding model (rats)
Dosage: Up to 30 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Crossed the blood-brain barrier and successfully entered the central nervous system, as evidenced by its ability to displace the in vivo binding of the radioligand [125I]RTI-55 in the rat caudate.
Animal Model: Swiss-Webster mice locomotor activity model
Dosage: 1.0, 3.0, 10, 20, 30, 40, 56, 100, and 170 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Exhibited less effectiveness in stimulating locomotion, and was ineffective in the first 30 minutes after injection.
Increased horizontal ambulatory activity at later times over the course of the observation period to a maximum mean of 266 counts/min at the 100 mg/kg dose from 60 to 90 minutes after injection.
Animal Model: Cocaine/saline drug-discrimination procedure in Swiss-Webster mice
Dosage: 3.0, 10, 17, 30, and 56 mg/kg (for 5-min pre-session treatment); 10, 30, 56, and 100 mg/kg (for 60-min pre-session treatment)
Administration: Intraperitoneal injection (i.p.), single dose
Result: Incompletely substituted for cocaine, reaching a maximum of approximately 60% to 68% drug-lever responding at 5 minutes or 1 hour after injection.
Produced a level of substitution greater than that produced by saline, although some subjects showed full substitution at some doses while others showed less than 33% drug-appropriate responding.
Produced dose-related decreases in rates of responding, with decreases at 5 minutes occurring at lower doses than at 60 minutes after injection.
Animal Model: Cocaine self-administration and substitution model in male Sprague-Dawley rats
Dosage: 0.01, 0.032, 0.1, 0.32, and 1.0 mg/kg/injection (unit doses under a five-component procedure)
Administration: Intravenous injection (i.v.), single dose
Result: Maintained low response rates throughout the experimental session that were not different from those obtained when saline injections were available.
Maintained response rates well below those maintained by cocaine, and showed no significant differences between any dose per injection compared with the extinction component.
Demonstrated that the compound itself was not self-administered.
Animal Model: Presession treatment on cocaine self-administration in male Sprague-Dawley rats
Dosage: 1.0, 3.2, 10, and 17 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Dose-dependently decreased maximal cocaine self-administration more potently than food-maintained responding, with ED50 values of 3.33 mg/kg for cocaine-maintained responding and 8.21 mg/kg for food presentation.
Produced an insurmountable antagonism of cocaine self-administration, shifting the cocaine self-administration dose-effect curve downward rather than leftward.
Increased the pauses before initiation of responding and caused responding to cease before the end of the components at the 10 mg/kg dose, where no dose of cocaine maintained responding above saline levels.
Animal Model: In vivo [125I]RTI-121 binding and DAT occupancy model in Swiss-Webster mice
Dosage: 3.0, 10, 30, and 56 mg/kg
Administration: Intraperitoneal injection (i.p.) for compound; intravenous injection (i.v.) via tail vein for [125I]RTI-121; single dose
Result: Produced a dose- and time-related displacement of [125I]RTI-121 binding in the striatum, reaching maximum displacement with 56 mg/kg at 60 min.
Exhibited the least steep slopes fitted to the time course of displacement among tested drugs, with a displacement rate of 0.320%/min at 56 mg/kg.
Demonstrated the slowest apparent association rate and in vivo DAT occupancy among tested drugs, approximately one-half of RTI-336 and one-fourth of cocaine.
Animal Model: Locomotor activity model in cannabinoid CB1 receptor wild-type and knockout mice
Dosage: 3.0, 10, and 30 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Increased horizontal ambulatory activity from 60 to 90 min after injection, with maximum mean ambulatory counts of 100 and 74.4 counts/min at 30 mg/kg for wild-type and knockout mice, respectively.
Stimulated activity from 120 to 150 min after injection but was less effective.
Showed no significant effect of genotype or dose-dependent differences, indicating that cannabinoid CB1 receptors do not decrease its cocaine-like stimulation or mediate its unique effects.

化学信息

分子量 392.92
分子式 C24H25ClN2O
CAS No. 652978-45-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础